56.84
+1.17 (+2.10%)
USD · OTCQX
52-week range
38.84
58.98
Trading at 89% of the 52-week range
Market Cap
354.98B
P/E Ratio
22.28
Forward P/E
16.42
Book Value
6.16
Div. Yield
2.88%
% Institutions
0.516%
% Insiders
0.00%

1 Year

+31.8%

3 Year

+81.1%

10 Year

+169.7%
Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.

Actions

Add an action for RHHBY.US, or sign in to see your action list.

Company Information

▼
Company Name
Roche Holding Ltd ADR
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
OTCQX
CIK: 0000889131
Currency: USD
Full Time Employees: 103,249
Phone: 41 61 688 88 80
Website: roche.com
Fiscal Year End: December
Description:

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.

Address:

Grenzacherstrasse 124, Basel, Switzerland, 4070

People

▼

Directors & Officers

Name Title Year Born
Dr. Severin Schwan Ph.D. Executive Chairman 1967
Dr. Thomas Schinecker Group Chief Executive Officer 1975
Dr. Alan Hippe Chief Financial Officer 1967
Ms. Wafaa Mamilli Chief Digital & Technology Officer 1967
Dr. Bruno Eschli Head of Investor Relations NA
Ms. Claudia Bockstiegel General Counsel 1964
Dr. Nina Schwab-Hautzinger Head of Group Communications 1975
Ms. Maria Cristina A. Wilbur Chief People Officer 1967
Dr. Nicolas Dunant Head of Group Media Relations NA
Mr. Boris L. Zaitra Head of Corporate Business Development 1972

Financial Highlights

▼
Market Cap: $354.98B
EBITDA: $23.96B
P/E Ratio: $22.28
PEG Ratio: $1.65
Book Value: $6.16
Dividend/Share: $9.80
Dividend Yield: 2.88%
Earnings/Share: $2.50
Profit Margin: 19.60%
Operating Margin: 36.20%
ROA (TTM): 13.51%
ROE (TTM): 38.11%
Revenue (TTM): $62.96B
Revenue/Share (TTM): $9.89
Earnings Growth (YOY): -7.70%
Revenue Growth (YOY): -1.20%

Valuation Metrics

Enterprise Value: $380.94B
Trailing P/E: 22.28
Forward P/E: 16.42

Shares Statistics

Shares Outstanding: 5.52B
Shares Float: 5.79B
% Insiders: 0.00%
% Institutions: 0.516%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$63.36B
Cost of Goods Sold
adjust
$-16.65B
Gross Profit
subtotal
$46.71B
SG&A
adjust
$-15.16B
R&D
adjust
$-13.35B
Other Operating Expense
adjust
$-16.37B
Operating Income
subtotal
$18.48B
Other / Non-Operating Items
adjust
$-5.60B
Net Income
subtotal
$12.88B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about RHHBY.US!